| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Oncology, Markers, Clinical Correlates |
Department of Surgery, City Hospital, Nottingham, NG5 1PB, United Kingdom [F. S. K., R. W. B., J. F. R. R.]; The Breast Cancer Unit, Tenovus Cancer Research Centre, University of Wales College of Medicine, Cardiff, CF4 4XX, United Kingdom [J. M. W. G., R. I. N.]; and Cancer Research Program, Garvan Institute of Medical Research, St. Vincent’s Hospital, Sydney, New South Wales 2010, Australia [R. H., E. A. M., R. L. S.]
Cyclin D1 is a key cell cycle regulatory protein with demonstrated oncogenic activity in a variety of malignancies. Cyclin D1 mRNA and protein are overexpressed in approximately 50% of primary breast carcinomas; however, the pathophysiological consequences of increased expression remain unclear. To investigate the functional sequelae of cyclin D1 mRNA overexpression, we analyzed clinical outcome in relation to the cyclin D1 mRNA level in 253 primary breast cancer patients (median follow-up, 75 months) with particular reference to estrogen receptor (ER) status and endocrine response. Overall, with the exception of the relationship between cyclin D1 mRNA expression and the ER, cyclin D1 mRNA was not associated with other clinicopathological features such as age, menopausal status, axillary lymph node status, vascular invasion, tumor size, type, and grade. However, in patients with ER-positive tumors (n = 182), high levels of cyclin D1 mRNA were associated with increased risk of relapse (P = 0.0016), local recurrence (P = 0.025), metastasis (P = 0.019), and death (P = 0.025). In contrast, there were no clinical correlations with cyclin D1 expression in ER-negative disease (n = 71). In 33 patients who received endocrine therapy for their primary or recurrent breast cancers, there was an apparent association between a high cyclin D1 mRNA level and a shorter response duration within the ER-positive subgroup (P = 0.04). Our findings indicate that overexpression of cyclin D1 mRNA correlates with a worse prognosis within the ER-positive breast cancer phenotype and may be a contributing factor to the development of endocrine resistance in ER-positive disease.
This article has been cited by other articles:
|
|
 |
|
  A. Thakur, Y. Sun, A. Bollig, J. Wu, H. Biliran, S. Banerjee, F. H. Sarkar, and D. J. Liao Anti-invasive and Antimetastatic Activities of Ribosomal Protein S6 Kinase 4 in Breast Cancer Cells Clin. Cancer Res., July 15, 2008; 14(14): 4427 - 4436. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Satoh, S. Hamada, K. Kimura, A. Kanno, M. Hirota, J. Umino, W. Fujibuchi, A. Masamune, N. Tanaka, K. Miura, et al. Up-Regulation of MSX2 Enhances the Malignant Phenotype and Is Associated with Twist 1 Expression in Human Pancreatic Cancer Cells Am. J. Pathol., April 1, 2008; 172(4): 926 - 939. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Rudas, M. Lehnert, A. Huynh, R. Jakesz, C. Singer, S. Lax, W. Schippinger, O. Dietze, R. Greil, W. Stiglbauer, et al. Cyclin D1 Expression in Breast Cancer Patients Receiving Adjuvant Tamoxifen-Based Therapy Clin. Cancer Res., March 15, 2008; 14(6): 1767 - 1774. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Trent, C. Yang, C. Li, M. Lynch, and E. V. Schmidt Heat Shock Protein B8, a Cyclin-Dependent Kinase Independent Cyclin D1 Target Gene, Contributes to Its Effects on Radiation Sensitivity Cancer Res., November 15, 2007; 67(22): 10774 - 10781. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. K. Saxena, P. M. Vertino, F. A. Anania, and D. Sharma Leptin-induced Growth Stimulation of Breast Cancer Cells Involves Recruitment of Histone Acetyltransferases and Mediator Complex to CYCLIN D1 Promoter via Activation of Stat3 J. Biol. Chem., May 4, 2007; 282(18): 13316 - 13325. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Kilker and M. D. Planas-Silva Cyclin D1 Is Necessary for Tamoxifen-Induced Cell Cycle Progression in Human Breast Cancer Cells Cancer Res., December 1, 2006; 66(23): 11478 - 11484. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Ishii, A. Pirkmaier, J. V. Alvarez, D. A. Frank, I. Keselman, D. Logothetis, J. Mandeli, M. J. O'Connell, S. Waxman, and D. Germain Cyclin d1 overexpression and response to bortezomib treatment in a breast cancer model. J Natl Cancer Inst, September 6, 2006; 98(17): 1238 - 1247. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Aiello, G. Pandini, F. Frasca, E. Conte, A. Murabito, A. Sacco, M. Genua, R. Vigneri, and A. Belfiore Peroxisomal Proliferator-Activated Receptor-{gamma} Agonists Induce Partial Reversion of Epithelial-Mesenchymal Transition in Anaplastic Thyroid Cancer Cells Endocrinology, September 1, 2006; 147(9): 4463 - 4475. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J-R Weng, C-Y Chen, J J Pinzone, M D Ringel, and C-S Chen Beyond peroxisome proliferator-activated receptor {gamma} signaling: the multi-facets of the antitumor effect of thiazolidinediones. Endocr. Relat. Cancer, June 1, 2006; 13(2): 401 - 413. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Colozza, E. Azambuja, F. Cardoso, C. Sotiriou, D. Larsimont, and M. J. Piccart Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? Ann. Onc., November 1, 2005; 16(11): 1723 - 1739. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Wang, S. Fan, Z. Li, M. Fu, M. Rao, Y. Ma, M. P. Lisanti, C. Albanese, B. S. Katzenellenbogen, P. J. Kushner, et al. Cyclin D1 Antagonizes BRCA1 Repression of Estrogen Receptor {alpha} Activity Cancer Res., August 1, 2005; 65(15): 6557 - 6567. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. M. Shah, M. Al-Dhaheri, Y. Dong, C. Ip, F. E. Jones, and B. G. Rowan Selenium disrupts estrogen receptor {alpha} signaling and potentiates tamoxifen antagonism in endometrial cancer cells and tamoxifen-resistant breast cancer cells Mol. Cancer Ther., August 1, 2005; 4(8): 1239 - 1249. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J Butt, C. M McNeil, E. A Musgrove, and R. L Sutherland Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E Endocr. Relat. Cancer, July 1, 2005; 12(Supplement_1): S47 - S59. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-W. Huang, C.-W. Shiau, Y.-T. Yang, S. K. Kulp, K.-F. Chen, R. W. Brueggemeier, C. L. Shapiro, and C.-S. Chen Peroxisome Proliferator-Activated Receptor {gamma}-Independent Ablation of Cyclin D1 by Thiazolidinediones and Their Derivatives in Breast Cancer Cells Mol. Pharmacol., April 1, 2005; 67(4): 1342 - 1348. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Dong, J. Peng, H. Zhang, W. H. Mondesire, W. Jian, G. B. Mills, M.-C. Hung, and F. Meric-Bernstam Role of Glycogen Synthase Kinase 3{beta} in Rapamycin-Mediated Cell Cycle Regulation and Chemosensitivity Cancer Res., March 1, 2005; 65(5): 1961 - 1972. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Chen and J. Xu Activation of PPAR{gamma} by curcumin inhibits Moser cell growth and mediates suppression of gene expression of cyclin D1 and EGFR Am J Physiol Gastrointest Liver Physiol, March 1, 2005; 288(3): G447 - G456. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Chu, K. Blackwell, S. Chen, and J. Slingerland The Dual ErbB1/ErbB2 Inhibitor, Lapatinib (GW572016), Cooperates with Tamoxifen to Inhibit Both Cell Proliferation- and Estrogen-Dependent Gene Expression in Antiestrogen-Resistant Breast Cancer Cancer Res., January 1, 2005; 65(1): 18 - 25. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L Hilakivi-Clarke, C Wang, M Kalil, R Riggins, and R G Pestell Nutritional modulation of the cell cycle and breast cancer Endocr. Relat. Cancer, December 1, 2004; 11(4): 603 - 622. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Alao, E. W-F. Lam, S. Ali, L. Buluwela, W. Bordogna, P. Lockey, R. Varshochi, A. V. Stavropoulou, R. C. Coombes, and D. M. Vigushin Histone Deacetylase Inhibitor Trichostatin A Represses Estrogen Receptor {alpha}-Dependent Transcription and Promotes Proteasomal Degradation of Cyclin D1 in Human Breast Carcinoma Cell Lines Clin. Cancer Res., December 1, 2004; 10(23): 8094 - 8104. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Wang, N. Pattabiraman, J. N. Zhou, M. Fu, T. Sakamaki, C. Albanese, Z. Li, K. Wu, J. Hulit, P. Neumeister, et al. Cyclin D1 Repression of Peroxisome Proliferator-Activated Receptor {gamma} Expression and Transactivation Mol. Cell. Biol., September 1, 2003; 23(17): 6159 - 6173. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. C. Hodges, J. D. Cook, E. K. Lobenhofer, L. Li, L. Bennett, P. R. Bushel, C. M. Aldaz, C. A. Afshari, and C. L. Walker Tamoxifen Functions As a Molecular Agonist Inducing Cell Cycle-Associated Genes in Breast Cancer Cells Mol. Cancer Res., February 1, 2003; 1(4): 300 - 311. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Hui, G. L. Finney, J. S. Carroll, C. S. L. Lee, E. A. Musgrove, and R. L. Sutherland Constitutive Overexpression of Cyclin D1 but not Cyclin E Confers Acute Resistance to Antiestrogens in T-47D Breast Cancer Cells Cancer Res., December 1, 2002; 62(23): 6916 - 6923. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Musgrove, L.-J. K. Hunter, C. S. L. Lee, A. Swarbrick, R. Hui, and R. L. Sutherland Cyclin D1 Overexpression Induces Progestin Resistance in T-47D Breast Cancer Cells Despite p27Kip1 Association with Cyclin E-Cdk2 J. Biol. Chem., December 7, 2001; 276(50): 47675 - 47683. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z.-Q. Ma, Z. Liu, E. S. W. Ngan, and S. Y. Tsai Cdc25B Functions as a Novel Coactivator for the Steroid Receptors Mol. Cell. Biol., December 1, 2001; 21(23): 8056 - 8067. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. Holley, G. Parkes, C. Matthias, U. Bockmuhl, V. Jahnke, K. Leder, R. C. Strange, A. A. Fryer, and P. R. Hoban Cyclin D1 Polymorphism and Expression in Patients with Squamous Cell Carcinoma of the Head and Neck Am. J. Pathol., November 1, 2001; 159(5): 1917 - 1924. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S A J Vaziri, R R Tubbs, G Darlington, and G Casey Absence of CCND1 gene amplification in breast tumours of BRCA1 mutation carriers Mol. Pathol., August 1, 2001; 54(4): 259 - 263. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Hui, R. D. Macmillan, F. S. Kenny, E. A. Musgrove, R. W. Blamey, R. I. Nicholson, J. F. R. Robertson, and R. L. Sutherland INK4a Gene Expression and Methylation in Primary Breast Cancer: Overexpression of p16INK4a Messenger RNA Is a Marker of Poor Prognosis Clin. Cancer Res., July 1, 2000; 6(7): 2777 - 2787. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
